

Clinical Trial Protocol

Iranian Registry of Clinical Trials

27 Jun 2026

Investigation of the effect of "Finasterid" on the prognosis in the hospitalized over 50 years male patients with COVID-19 pneumonia

Protocol summary

Study aim

Investigation of the effect of Finasterid on the prognosis of the hospitalized over 50 years male patients with COVID-19 pneumonia

Design

Phase 3 double-blind randomized controlled clinical trial , on 80 patients. Randomization method is the use of online software to generate random numbers of KitSet.

Settings and conduct

prescription of finastride in 80 patients with COVID-19 pneumonia in Qazvin's Bu Ali Sina hospital. This study will be double-blind and both the patient and the evaluator will be unaware of the type of treatment performed.

Participants/Inclusion and exclusion criteria

males with coronavirus pneumonia over 50 years old No entry: use of finasterid before covid-19

Intervention groups

In the intervention group, one dose of finastride tablets will be taken daily for 5 days. In the control group, the placebo will be prescribed for the same period.

Main outcome variables

saturation diseases period mortality

General information

Reason for update

Acronym

IRCT registration information

IRCT registration number: **IRCT20200505047318N1**

Registration date: **2020-08-06, 1399/05/16**

Registration timing: **retrospective**

Last update: **2020-08-06, 1399/05/16**

Update count: **0**

Registration date

2020-08-06, 1399/05/16

Registrant information

Name

Elham Zarehoseinzade

Name of organization / entity

Country

Iran (Islamic Republic of)

Phone

+98 26 3320 3252

Email address

e.zarehoseinzade@qums.ac.ir

Recruitment status

Recruitment complete

Funding source

Expected recruitment start date

2020-03-20, 1399/01/01

Expected recruitment end date

2020-06-20, 1399/03/31

Actual recruitment start date

empty

Actual recruitment end date

empty

Trial completion date

empty

Scientific title

Investigation of the effect of "Finasterid" on the prognosis in the hospitalized over 50 years male patients with COVID-19 pneumonia

Public title

Effect of finasterid on COVID-19 treatment

Purpose

Treatment

Inclusion/Exclusion criteria

Inclusion criteria:

having covid-19 age>50 years male hospitalization

Exclusion criteria:

use finasterid before covid-19 neurologic disease psychiatric disease drug users

Age

From **50 years** old

Gender

Male

Phase

3

Groups that have been masked

- Participant
- Outcome assessor

Sample size

Target sample size: **80**

Randomization (investigator's opinion)

Randomized

Randomization description

Patients were numbered from 6 to 6. Randomization method was performed using KitSet software (<https://kitset.ir/numbers/random>) for generating random numbers for A and B and based on the result, they were ranked from 1 to 3, respectively. Group A received finasteride and group B received placebo.

Blinding (investigator's opinion)

Double blinded

Blinding description

This study will be double-blind and both the patients and the evaluator will be unaware of the type of treatment performed. Despite the detailed explanation of the study while obtaining the consent of group A or B will not be stated. The evaluator will not be aware of this.

Placebo

Used

Assignment

Parallel

Other design features**Secondary Ids**

empty

Ethics committees**1****Ethics committee****Name of ethics committee**

Ethics Committee of Qavin University of Medical Sciences

Street address

Booali.Ave

City

Qhazvin

Province

Qazvin

Postal code

3413786313

Approval date

2020-04-21, 1399/02/02

Ethics committee reference number

IR.QUMS.REC.1399.016

Health conditions studied**1****Description of health condition studied**

Corona virus pneumonia

ICD-10 code

U07.2

ICD-10 code description

COVID-19, virus not identified

Primary outcomes**1****Description**

o2 saturation of blood

Timepoint

initial/fifth day of hospitalization

Method of measurement

pulse oximeter

Secondary outcomes

empty

Intervention groups**1****Description**

Intervention group : Tab.HCQ 200,Po,Q12h/Amp.Ceftriaxon,1 gr,IV.Q12h/ TTab.finasteride 5mg,PO,Daily,5 days

Category

Treatment - Drugs

2**Description**

Control group: Tab.HCQ 200,Po,Q12h/Amp.Ceftriaxon,1 gr,IV.Q12h/ One placebo daily for 5 days

Category

Treatment - Drugs

Recruitment centers**1****Recruitment center****Name of recruitment center**

Qazvin Bu Ali Sina Hospital

Full name of responsible person

Dr.Abbas Allamy

Street address

Bu Ali.Ave

City

Qazvin

Province

Qazvin

Postal code

3413786313

Phone

+98 28 3333 2931

Email

allami@qums.ac.ir

2**Recruitment center****Name of recruitment center**

Bu Ali Sina

Full name of responsible person

Abbas Allamy

Street address

Bu Ali.Ave

City

Qazvin

Province

Qazvin

Postal code

3413786313

Phone

+98 28 3333 2931

Email

allami@qums.ac.ir

Sponsors / Funding sources1**Sponsor****Name of organization / entity**

Qazvin University of Medical Sciences

Full name of responsible person

Dr.Abbas Allami

Street address

Bu Ali Ave

City

Qazvin

Province

Qazvin

Postal code

3413786313

Phone

+98 28 3333 2931

Email

allami@qums.ac.ir

Grant name**Grant code / Reference number****Is the source of funding the same sponsor organization/entity?**

Yes

Title of funding source

Qazvin University of Medical Sciences

Proportion provided by this source

100

Public or private sector

Public

Domestic or foreign origin

Domestic

Category of foreign source of funding

empty

Country of origin**Type of organization providing the funding**

Academic

Person responsible for general inquiries**Contact****Name of organization / entity**

Qazvin University of Medical Sciences

Full name of responsible person

Dr.Abbas Allami

Position

Professor

Latest degree

Specialist

Other areas of specialty/work

Infectious diseases

Street address

Bu Ali Ave.

City

Qazvin

Province

Qazvin

Postal code

3413786313

Phone

+98 28 3333 2930

Email

allami@qums.ac.ir

Person responsible for scientific inquiries**Contact****Name of organization / entity**

Qazvin University of Medical Sciences

Full name of responsible person

Dr.Abbas Allami

Position

professor

Latest degree

Specialist

Other areas of specialty/work

Infectious diseases

Street address

Bu Ali Ave.

City

Qazvin

Province

Qazvin

Postal code

3413786313

Phone

+98 28 3333 2930

Email

allami@qums.ac.ir

Person responsible for updating data**Contact****Name of organization / entity**

Qazvin University of Medical Sciences

Full name of responsible person

Dr.Abbas Allami

Position

Professor

Latest degree

Subspecialist

Other areas of specialty/work

Infectious diseases

Street address

Bu Ali Ave.

City

Qazvin

Province

Qazvin

Postal code

3413786313

Phone

+98 28 3333 2930

Email

allami@qums.ac.ir

Sharing plan**Deidentified Individual Participant Data Set (IPD)**

Yes - There is a plan to make this available

Study Protocol

Yes - There is a plan to make this available

Statistical Analysis Plan

Yes - There is a plan to make this available

Informed Consent Form

Yes - There is a plan to make this available

Clinical Study Report

Yes - There is a plan to make this available

Analytic Code

Yes - There is a plan to make this available

Data Dictionary

Yes - There is a plan to make this available

Title and more details about the data/document

effect of finastride on improving the symptoms of covid-19 pneumonia

When the data will become available and for how long

access begins one year after the results are published

To whom data/document is available

Researchers working in academic and scientific institutions

Under which criteria data/document could be used

-Research on related issues

From where data/document is obtainable

Qazvin-Bu Ali Ave. Dr.Abbas Allami allami@qums.ac.ir

What processes are involved for a request to access data/document

it will be provided through coordination via email and presentation of documentation

Comments